In melanoma and fibrosarcoma, overexpression of EGFR and ERBB2 sensitizes tumors to ferroptosis-inducing treatments through activation of the RAS/RAF/c-Myc/ACSL4 signaling axis [33]. This evidence concerns the gene ERBB2 and fibrosarcoma.